OBJECTIVES: Drug-eluting stents (DESs) have been considered to be generally superior to bare-metal stents (BMSs) for its lower rates of target-vessel revascularization. The National Health Insurance (NHI) started reimbursing BMSs in July 1999. But when it came to DESs, balanced-billing was employed to reimburse DESs under the pressure of NHI's widening fi nancial defi cits. Patients who chose DESs would need to pay the differences between the price of DESs charged by providers and the fee schedule of BMSs set by NHI. Whether distribution of DESs would concentrate in patients with higher socioeconomic status remained an unanswered research question. This study aimed to examine the infl uence of socioeconomic factors on the choice between DESs and BMSs in Taiwan. METHODS: Patients who admitted in the hospitals for coronary stenting during December 1, 2006 to December 31, 2007 in the Taiwan National Health Insurance (NHI) claims database were identifi ed as the study cases. The Cox proportional hazard model was preformed to evaluate the relationship between socioeconomic factors and the likelihood of choosing DESs, controlling for other patients' demographical factors and providers' characteristics. RESULTS: There were 3773 cases of DESs and 7413 BMSs in the observation period. Patients who were with higher wage income level and residing in the northern part of Taiwan were signifi cantly more likely to choose DESs. Veterans and patients from low-income households were signifi cantly less likely to choose DESs. CONCLUSIONS: Socioeconomic factors seemed to be strong predictors of choosing DESs. Future research on the implications of disparities in using DESs is warranted to evaluate the impact of the balance-bill on equity of health in Taiwan.
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Kaohsiung Medical University, Kaohsiung, Taiwan; 2 University of Macau, Macau, Macau OBJECTIVES: This study aims to evaluate potential drug-drug interactions (DDIs) related to angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in Taiwan. METHODS: This cross-sectional study used a claim-based dataset published by the Taiwanese National Health Research Institute, constituting of data for 1,000,000 benefi ciaries randomly sampled in 2005 from the nationwide population and followed longitudinally from 1995 to 2008. Individual prescription data of hypertensive outpatients using ACEIs or ARBs were extracted from 2006 to 2008. Level-1 to Level-3 potential DDIs were identifi ed as the presence of interacting pairs defi ned by the "Drug Facts and Comparisons." Demographic of patients having potential DDIs, prescription details and prescription overlapping days (POD) were collected and presented in descriptive statistics. Frequency of potential DDIs was stratifi ed by three age bands and four POD ranges and evaluated by Wald chi-square tests. RESULTS: Of all, 23,299 DDI prescriptions were assessed, including 22,967 (98.58%) and 332 (1.42%) for ACEIs and ARBs. For ACEIs, the most common drug for potential Level-1 to Level-3 DDIs is amiloride (n = 3902, 16.99%), indomethacin (n = 624, 2.72%) and furosemide (n = 13137, 57.20%), respectively. For ARBs, the most frequent combined drug with Level-2 and Level-3 DDIs is lithium (n = 98, 29.52%) and indomethacin (n = 234, 70.48%). The majority of patients who had used DDI prescriptions aged over than 45 years (in the age bands of "45-65 years" and "over 65 year"), and the most frequent POD range for DDI prescriptions is during 16 to 30 days. CONCLUSIONS: Although there is only a small proportion of potential ACEIs/ARBs related DDI prescriptions in Taiwan, prescriptions are mostly prescribed for mid-age and elderly patients and frequently continued for 1 month. Further study will still need to explore the association between potential DDI prescriptions and adverse outcomes to justify the appropriateness of these prescriptions.
PCV36 PRESCRIPTION PATTERN OF DUAL ANTIPLATELET THERAPY AMONG TAIWANESE OLDER ADULTS
Yu IW 1 , Lin HW 2 1 China Medical University Hospital, Taichung, Taiwan; 2 China Medical University, Taichung, Taiwan OBJECTIVES: Upon the coverage restriction proposed by Taiwan National Health Insurance (NHI), the dual antiplatelet therapy (DAT) with clopidogrel and aspirin could be reimbursed up to 9 months for some specifi c indications since 2004. The longer duration of DAT was allowed for the cases with drug eluting stent (DES) since late 2006. Although evidence showed its risks outweighed the benefi ts comparing to use aspirin alone, it is a lack of study examining the population use of DAT in Taiwan. A secondary data analysis was performed to examine the use patterns of DAT, specifically among the older adults in Taiwan. METHODS: A population-based longitudinal assessment was conducted using the 2003-2007 NHI databases. Those benefi ciaries in 60 years old of age and greater during the study period were evaluated. All relevant data, including visits toward physician clinics, outpatient departments, use of medications, and pertinent covered cost in the datasets of ambulatory care were retrieved and analyzed. Descriptive analysis was performed to describe the utilization and duration of DAT. RESULTS: Of 1 million benefi ciaries being evaluated, 1511 older patients (age = 70.8 ± 8.0-year-olds) were prescribed DAT. A sharply increasing prescription of DAT occurred in 2007. 85.6% were prescribed with approval indications (i.e., ischemic heart diseases) for aspirin or clopidogrel alone. Thirty-one percent possessed with at least one atherothrombotic risk factors (DM, dyslipidemia), which might attribute to DAT. The duration of DAT was up to 13 months. About 10% had DAT for more than 9 months. CONCLUSIONS: A sharply increasing utilization of DAT among Taiwanese older adults occurred in 2007. The change of reimbursement policy for DES in Taiwan may be the major contributing factor. However, further studies are needed to explore other contributing factors of DAT and its effectiveness and safety outcomes.
PCV37 POTENTIAL FOR PATIENT CONFUSION FROM BRAND SUBSTITUTION OF STATINS IN AUSTRALIA
Ortiz MS 1 , Calcino G 2 1 University of NSW, Darlinghurst, NSW, Australia; 2 HI Connections, Canberra, ACT, Australia OBJECTIVES: To study the extent of brand substitution and brand switching between statins available on the Australian Pharmaceutical Benefi t Scheme (PBS). METHODS: PBS prescription claims provided by Medicare Australia of a 10% random sample of all Australian long-term concession card holders were assessed over the time period August 2007 through July 2008. Patients had to fi ll at least four prescriptions for a statin with generics (simvastatin [fi ve strengths with up to 17 brands], or pravastatin [four strengths with up to 12 brands]) over the 1-year period. The proportion of non-switchers (single brand only) and multiple switchers (two or more switches between brands) were determined for each strength of these statins. RESULTS: A total of 39,913 patients fi lled at least four prescriptions for a statin in the time window. The majority of Concessional patients received a single brand over the period (simvastatin at 60% and pravastatin at 56%). A smaller proportion received three or more brands: 14% for simvastatin to 13% for pravastatin. The proportion of statin scripts for the originator brand ranged from 22% for Zocor (simvastatin) to 36% for Pravachol (pravastatin). A substantial proportion of statin patients were multiple switchers: 23% for simvastatin and 25% for pravastatin. Neither the number of brands received nor the number of switches seemed to be affected by the number of brands available on the PBS. Multiple switching was more common in of those under 50 years (33%) compared with of those aged 70-79 years (23%). CONCLUSIONS: There is potential for patient confusion since there are multiple switches of both statins occurring in one quarter of these Australian statin patients. There was also a 43% increase in multiple switching by younger patients.
